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Modulation of the immune response against tumour cells is emerging as a valuable approach for cancer treatment. Some
experimental studies have shown that secretion of colony stimulating factors by cancer cells reduces their tumorigenicity
and increases their immunogenicity probably by promoting the cytolitic and antigen presenting activities of leukocytes.
We have observed that human colon cancer cells (HT-29) are able to secrete granulocyte-macrophage-colony
stimulating factor, granulocyte-colony stimulating factor and macrophage-colony stimulating factor when stimulated with
cytokines (IL-1b and TNF-a). In this study we assessed, for the ﬁrst time, the effects of several anticancer drugs on
colony stimulating factor release or apoptosis in HT-29 cells. Cytokine-induced release of granulocyte-macrophage-colony
stimulating factor, granulocyte-colony stimulating factor and macrophage-colony stimulating factor was signiﬁcantly
increased by cisplatin and 6-mercaptopurine. Taxol only increased macrophage-colony stimulating factor release while
reduced that of granulocyte-colony stimulating factor. No changes in colony stimulating factor secretion were observed
after treatment with methotrexate. Only cisplatin and taxol induced apoptosis in these cells. Secretion of colony
stimulating factors by colon cancer cells may contribute to the immune host response against them. Anticancer drugs
such as cisplatin and 6-mercaptopurine increase colony stimulating factor secretion by cytokine stimulated cancer cells
probably through mechanisms different to those leading to cell apoptosis, an effect that may contribute to their anti-
neoplasic action.
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Treatment of cancer widely relies on the use of cytotoxic
drugs. Anticancer drugs interfere with different steps involved
in the processes of cell division and so damage cancerous
cells. In many instances these drug effects are now known
to be via inﬂuences on the apoptotic pathway. In addition,
there is now an increasing interest in manipulating the body’s
immune response against cancer cells. Indeed, genetic therapies
aimed at increasing the secretion of certain cytokines by
cancer cells seem to have potential as a mode of increasing
the host response against tumour progression (Dranoff and
Mulligan, 1995; Ettinghausen and Rosenberg, 1995). In particu-
lar, increasing the secretion of the colony stimulating factors
(CSFs) granulocyte-macrophage-CSF (GM-CSF) or granulocyte-
CSF (G-CSF) by colon adenocarcinoma, melanoma, lung or
renal carcinoma, ﬁbrosarcoma, B-cell lymphoma or acute
myeloid leukemic cells prevents the formation of tumours by
these cells and results in the elimination of pre-established
cancer in mice (Colombo et al, 1991; Dranoff et al, 1993;
Armstrong et al, 1996; Levitsky et al, 1996; Dunussi-Joanno-
poulos et al, 1998).
In addition to their recently noted effects on cancer cells,
CSFs such as G-CSF, GM-CSF or macrophage-CSF (M-CSF)
have multiple biological activities. These biological activities
include the ability to stimulate the proliferation and differentia-
tion of multipotential bone marrow progenitor cells into
mature granulocytes and macrophages (Fleischmann et al,
1986). There is evidence that CSFs stimulate the phagocytic
and cytocidal activity of macrophages (Handman and Burgess,
1979; Ho et al, 1990) and promote monocyte and neutrophil
antibody-dependent cellular cytotoxicity (Kushner and Cheung,
1989; Liesveld et al, 1991). They may also play a major role
in the maturation of dendritic cells into potent activators of
resting T cells (Morrissey et al, 1987). In fact, the beneﬁcial
effect of CSF secretion by cancer cells appears to be due to
the increased recruitment and activity of phagocytic cells as
well as to an enhancement of the antigen presentation activity
and T-cell mediated cytotoxicity.
We have observed that human colon cancer cells are able
to secrete G-CSF, M-CSF and GM-CSF (Calatayud et al,
2001). However, the mechanisms modulating these releases
are incompletely understood. Moreover, the potential effects
of anti-cancer drugs on CSF release by these cells have not
been investigated. Thus, here we have assessed the inﬂuences
of a number of different anticancer drugs on the release of
G-CSF, M-CSF and GM-CSF. Additionally, we have evaluated
whether the effects of these drugs on CSF secretion depend
upon the induction of cell apoptosis.
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Cell culture
HT-29 cells (Human Caucasian Colon adenocarcinoma Grade II)
were obtained from the European Collection of Animal Cell
Culture. Cells were seeded at a density of 2610
4 per well in 96-
well plates, cultured in McCoy’s medium with 2 mmol l
71 gluta-
mine and 10% foetal calf serum (378C, 5% CO2) and grown in
monolayers to conﬂuency. Cells were serum starved for 24 h prior
to use. In preliminary studies, cells were stimulated with different
combinations of cytokines (Table 1) and interleukin-1ß (IL-1b,
10 ng ml
71, Roche) plus tumour necrosis factor a (TNF-
a,10 ng ml
71, Roche) was selected as the optimal treatment for a
consistent release of CSFs. The effects of these cytokines on CSF
secretion were evaluated in the presence or absence of different
concentrations (10
711–10
74 M) of 6-mercaptopurine (6-MP),
cisplatin, taxol, colchicine or methotrexate (all from Sigma). In
some experiments, cells were treated with cycloheximide
(10
76 M) at the time of, or 6 h before, cytokine addition. Medium
was removed 24 h after cytokine treatment for the measurement of
CSFs. Each treatment was tested in triplicate, on a minimum of
three separate occasions.
Measurement of CSFs
The concentrations of GM-CSF, G-CSF and M-CSF were measured
in cell culture supernatant using speciﬁc ELISAs constructed from
commercially available components. In brief, 96-well plates were
coated with the correspondent capture antibodies (rat anti human
GM-CSF, G-CSF or M-CSF, R&D systems). Following 1 h blocking
(1% BSA, 5% sucrose and 0.05% NaN3 in PBS, 100 ml well
71),
100 ml of standard or undiluted cell culture supernatant was added
and incubation continued for a further 2 h. The wells were subse-
quently incubated with the respective detection antibodies (rat anti
human GM-CSF, G-CSF or M-CSF, R&D systems, 2 h) and strep-
tavidin peroxidase (Sigma, 30 min). Finally, 100 ml of substrate
solution (1:1 mixture of tetramethylbenzidine and hydrogen perox-
ide) was added and the reaction stopped 30 min later by addition
of 50 mlo f1NH 2SO4. Absorbance was then read at 450 nm (l
correction 550 nm) and the concentrations of CSFs calculated from
the standard curves.
Measurement of apoptosis
At the end of each treatment the level of apoptosis was evaluated.
Apoptosis was measured by the degree of cytoplasmic histone asso-
ciated DNA fragments (mono- and oligonucleosomes) by ELISA
(Programmed Cell Death Detection ELISA, Roche) according to
the manufacturer’s recommendations. Brieﬂy, the medium was
removed and the cells lysed in 200 ml of the lysis buffer provided.
The lysate was centrifuged and 20 ml of supernatant added to a
streptavidin-coated microtiter plate with a mixture of mouse
biotin-labelled anti-histone and mouse peroxidase-conjugated
anti-DNA. After 2 h-incubation period, the plate was washed and
the retained peroxidase determined photometrically with ABTS
(2,2'-azino-di-[3-ethylbenzthiazoline sulphonate]) as a substrate.
Optical density was measured at 405 nm (l correction 492 nm).
Measurement of viable cell number (MTT assay)
Cellular respiration was assessed by mitochondrial-dependent
reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT, Sigma) to formazan. At the end of the experiment,
medium was removed from the cells and replaced with 100 mlo f
warm (378C) medium containing 0.2 mg ml
71 of MTT. After
incubation for a further 30 min at 378C the medium containing
the MTT was removed and the cells dissolved in 100 ml dimethyl
sulphoxide (DMSO). The extent of MTT conversion to formazan
was quantiﬁed by measurement of optical density at 550 nm with
a wavelength correction of 650 nm.
RESULTS
CSF production by HT-29 cells
In the absence of cytokines, HT-29 cells released low or undetect-
able levels of GM-CSF, G-CSF or M-CSF. However, these cells can
be stimulated with common pro-inﬂammatory cytokines to secrete
CSFs (Table 1). Preliminary studies aimed to select the optimal
treatment for a consistent release of CSFs showed an increased
GM-CSF secretion after a 24 h-incubation period with IL-1b
(10 ng ml
71). This response was signiﬁcantly enhanced by co-
treatment with TNF-a at a concentration devoid of any secretory
effect per se (10 ng ml
71). The combined action of IL-1b plus
TNF-a was further enhanced by interferon-g (1000 U ml
71)o r
interleukin-6 (2 mgm l
71) (Table 1) although in these cases, signif-
icant reductions in the number of viable cells were observed (data
not shown). Secretion of G-CSF and M-CSF was also signiﬁcantly
increased by IL-1b plus TNF-a (10 ng ml
71 both, 24 h) (Figure 1)
and thus, this combination of cytokines was selected for cell stimu-
lation.
Cytokine-induced release of CSFs was tested in the presence of
several anti-cancer drugs with different mechanisms for their
anti-neoplasic action. Incubation with the purine analogue 6-MP
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Table 1 Release of GM-CSF by HT-29 cells in the presence or absence
of different cytokines (24 h)
IL-1b TNF-a IFN-g IL-6 GM-CSF
(10 ng ml
71) (10 ng ml
71) (1000 U ml
71)( 2 mgm l
71) (pg ml
71)
77 7 7 1+1
+ 77 7 38+9
7 + 77 5+5
77 + 7 2+2
77 7 +2 +2
++ 77 90+11***
+ 7 + 7 67+12*
7 ++ 7 43+7
++ + 7 184+36***
++ 7 + 144+23***
Results expressed mean+s.e.m. (n=3 per group). *P50.05 and ***P50.001 vs
control value (ANOVA+Dunnet test).
150
100
50
0
C
S
F
 
r
e
l
e
a
s
e
 
(
p
g
 
m
l
–
1
)
***
control
IL-1b + TNFa
***
***
GM-CSF M-CSF G-CSF
Figure 1 Release of GM-CSF, M-CSF and G-CSF by HT-29 cells in the
presence or absence of IL-1b and TNF-a (both 10 ng ml
71, 24 h). Results
expressed as mean+s.e.m. (n=20 per group). ***P50.001 vs respective
control value (2-tailed Student’s t-test).
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76–10
74 M both)
induced signiﬁcant increases in GM-CSF, G-CSF and M-CSF secre-
tion by cytokine treated HT-29 cells (Figure 2). By contrast, the
inhibitor of microtubule depolymerisation taxol produced diver-
gent effects increasing M-CSF secretion, reducing G-CSF
secretion and leaving GM-CSF secretion unchanged (Figure 2).
Finally, the dihydrofolate reductase inhibitor methotrexate had
no effects upon the production of any of the CSFs (data not
shown).
In order to clarify the mechanism for the release of CSFs by HT-
29 cells after cytokine treatment, cells were incubated with an inhi-
bitor of protein synthesis (cycloheximide 10
76 M) or colchicine
(10
711–10
74 M), which induces microtubule depolymerisation.
Pre-treatment or co-treatment with cycloheximide inhibited cyto-
kine-induced release of GM-CSF and M-CSF but not that of G-
CSF (Figure 3). Colchicine (10
77–10
74 M) increased GM-CSF
and M-CSF secretion whilst it decreased that of G-CSF (Figure 4A).
HT-29 cell apoptosis and viability
Cisplatin and taxol signiﬁcantly increased apoptosis of HT-29 cells
24 h after treatment. Cell apoptosis was also augmented by IL-1b
plus TNF-a and this effect was additive to those of cisplatin or
taxol (Figure 5). The increase in apoptosis of HT-29 cells observed
after incubation with cytokines plus cytotoxic drugs was accompa-
nied by reductions in the number of viable cells (Table 2). 6-MP or
methotrexate did not induce HT-29 cell apoptosis in control condi-
tions or in the presence of cytokines at the time point used (Figure
5). However, when 6-MP was given to cells together with cytokines
a reduction in viable cell number was seen (Table 2). HT-29 cell
apoptosis was increased in the presence of colchicine and this effect
was not additive to that of the cytokines (Figure 4B).
Statistical analysis of the data showed no correlation between the
increases in apoptosis or the reductions in cell viability induced by
these drugs and their effects on the production of GM-CSF, G-CSF
or M-CSF (data not shown).
DISCUSSION
The functional effects of granulocytes, lymphocytes, and macro-
phages are important in patients with malignancies because of
the abilities of these cells to exhibit antitumour activities. Because
of these abilities, different immunotherapy strategies have been
assayed for cancer treatment. In experimental studies tumour
regression follows increases in the local release of different cyto-
kines that would induce the recruitment and activation of
immune cells (Dranoff and Mulligan, 1995; Ettinghausen and
Rosenberg, 1995). Indeed, CSFs have been shown to be amongst
the most potent immune response inducers in this setting (Colom-
bo et al, 1991; Dranoff et al, 1993; Armstrong et al, 1996; Levitsky
et al, 1996; Dunussi-Joannopoulos et al, 1998).
In the present study we conﬁrm our previous observations that
human colon cancer epithelial cells have the ability to produce
GM-CSF, G-CSF and M-CSF in response to cytokines commonly
found in the inﬂammatory responses (IL-1b and TNF-a), including
those that accompany tumour formation. Moreover, we have
shown, for the ﬁrst time, that the secretion of CSFs by colon cancer
cells stimulated with these cytokines is modiﬁed by different antic-
ancer drugs.
In our study the purine analogue 6-MP and the DNA-damaging
agent cisplatin acted similarly. They both increased the secretion of
all three CSF by cytokine-stimulated HT-29 cells. Colchicine, which
binds to a site on ß-tubulin and causes microtubule depolymerisa-
tion, also increased the release of GM-CSF and M-CSF, but
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Figure 2 Effects of 6-MP, cisplatin and taxol on the release of G-CSF, GM-CSF or M-CSF by cytokine stimulated HT-29 cells (IL-1b and
TNF-a, both 10 ng ml
71, 24 h). Results expressed as mean+s.e.m (n=5 per group). *P50.05, **P50.01 vs value in the respective vehicle-treated cells
(ANOVA+Dunnet test).
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Figure 3 Effects of cycloheximide (10
76 M) on the release of GM-CSF,
M-CSF or G-CSF by cytokine stimulated HT-29 cells (IL-1b and TNF-a,
both 10 ng ml
71, 24 h). Cycloheximide was added to the medium at
the same time or 6 h before cytokines. Results expressed as mean+s.e.m.
of the number of experiments shown above each column. *P50.05 and
***P50.001 vs value in the respective vehicle-treated cells (2-tailed Stu-
dent’s t-test).
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Figure 5 Effects of cisplatin, taxol, 6-MP and methotrexate on HT-29 cell apoptosis in the presence or absence of IL-1b and TNF-a (both 10 ng ml
71,
24 h). Results expressed as mean+s.e.m. (n=3 per group). *P50.05, **P50.01 and ***P50.001 vs control conditions,
+P50.05,
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depolymerisation, similarly increased M-CSF but decreased G-CSF
production and did not modify GM-CSF secretion. By contrast
methotrexate, an inhibitor of dihydrofolate reductase, failed to
affect the release of any CSF.
The aim of antineoplasic treatment with these drugs is to impair
mitosis in cancer cells, block progression through the cell cycle,
and so promote apoptosis. However, cancer cells often develop
resistance to chemotherapy, which may be drug-speciﬁc or
mediated by more general mechanisms such as the mutation of
p53 suppressor oncogene observed in HT-29 cells (Shao et al,
1996). Of the drugs tested in the present study only cisplatin, taxol
and colchicine induced apoptosis in HT-29 cells and no correla-
tions between changes in CSF secretion and induction of
apoptosis were observed in any case. For instance, similar effects
on CSF secretion were obtained with 6-MP and cisplatin, and only
cisplatin induced apoptosis in HT-29 cells.
Taxol and colchicine both modify microtubule formation and
both drugs reduced G-CSF secretion. However, the effects of taxol
and colchicine on GM-CSF and M-CSF release were different.
Colchicine induced a signiﬁcant increase in the release of both
cytokines. By contrast, taxol only increased M-CSF secretion and
only at concentrations that were much higher than those necessary
to modify microtubule function. Experiments performed in the
presence of cycloheximide suggested that the cytokine-induced
release of GM-CSF and M-CSF by HT-29 cells depends on de novo
protein synthesis, while G-CSF secretion does not. Taken together
these ﬁndings suggest that G-CSF secretion in response to cyto-
kines occurs via a tubulin driven release of pre-formed G-CSF.
Previous studies have shown that cisplatin and taxol modify the
function of immune cells. For example, treatment with these drugs
induces an increase in the secretion of pro-inﬂammatory cytokines
by leukocytes, especially monocytes and macrophages, which is
usually accompanied by an enhanced activity and cytotoxicity
against cancer cells (Bogdan and Ding, 1992; Gan et al, 1992;
Suresh and Sodhi, 2001). The present results extend our knowledge
of the immunomodulatory effects of cisplatin and taxol, showing
that these drugs regulate the synthesis and secretion of CSFs by
cytokine-stimulated cancer cells. More unexpected were the results
obtained with 6-MP, a drug that besides its action as antineoplasic
agent is used in the treatment of chronic inﬂammatory circum-
stances such as Crohn’s disease. Its utility in Crohn’s disease
appears due to its immunosupressive effects, although it has also
been demonstrated to have some anti-inﬂammatory properties
(Goldstein, 1987). However, treatment of HT-29 cells with 6-MP
induced a signiﬁcant increase in the cytokine-induced release of
GM-CSF, G-CSF and M-CSF.
Secretion of CSFs by cancer cells has important consequences for
tumour progression. For instance, in murine models of colon
adenocarcinoma, melanoma or acute myeloid leukaemia transfec-
tion of cancer cells with genes to overexpress G-CSF or GM-CSF
results in reduced tumorigenicity (Colombo et al, 1991; Armstrong
et al, 1996; Dunussi-Joannopoulos et al, 1998). Additionally, injec-
tion of irradiated tumour cells expressing murine GM-CSF
produces potent, speciﬁc and long-lasting anti-tumour immunity
and even induces regression of pre-established cancer (Dranoff
and Mulligan, 1995; Armstrong et al, 1996; Levitsky et al, 1996;
Dunussi-Joannopoulos et al, 1998). Likewise, some preliminary
clinical trials testing the therapeutic potential of systemic GM-
CSF administration have produced encouraging results (Armitage,
1998). Rejection of CSF-secreting cancer cells appears to be because
they increase the recruitment and activity of phagocytic cells, while
the speciﬁc immunisation is probably related to the enhanced anti-
gen presentation activity and T-cell mediated cytotoxicity.
Increased levels of CSFs following systemic administration may also
have beneﬁcial effects by helping to reverse the defective antigen
presentation and tumoricidal activities that are found in mononuc-
lear phagocytes isolated from cancer patients (Kleinerman et al,
1980). However, a localised release of these cytokines would have
extra beneﬁts by attracting the inﬂammatory cells to the tumour
and facilitating their contact with the cancer cells, as pointed out
by some experimental studies (Colombo et al, 1991; Armstrong
et al, 1996). Our ﬁndings suggest that changes in the secretion of
CSFs by cancer cells themselves after treatment with anticancer
drugs, may be of signiﬁcance for the immune response against
those cells. This may be particularly important when considering
the mechanism of action of drugs such as cisplatin and 6-MP.
Thus, we suggest that treatment with these drugs may modulate
the host immune response against cancer cells and this could
contribute to their anti-neoplasic action. New investigations are
required to analyse whether these effects take place in vivo and
whether anticancer drugs act preferentially in cancer cells.
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